Robert W. Baird Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)

Robert W. Baird analyst Joel Beatty maintained a Buy rating on IDEAYA Biosciences (IDYAResearch Report) on July 27 and set a price target of $26.00. The company’s shares closed last Thursday at $15.00.

According to, Beatty is a 3-star analyst with an average return of 3.0% and a 50.0% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on IDEAYA Biosciences is a Strong Buy with an average price target of $21.00.

See today’s best-performing stocks on TipRanks >>

IDEAYA Biosciences’ market cap is currently $605.5M and has a P/E ratio of -10.62.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Read More on IDYA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More